IBI188 Combination Therapy in Solid Tumors

Summary

A Phase Ib study aim to evaluate the efficacy, safety, and tolerability of IBI188 combination therapy in subjects with advanced malignancies

Conditions

• Solid Tumors
• Lung Adenocarcinoma
• Osteosarcoma

Interventions

DRUG

IBI188

intravenous

DRUG

GM-CSF

subcutaneous injection

DRUG

Cisplatin/Carboplatin

intravenous

DRUG

Bevacizumab

intravenous

DRUG

Sintilimab

intravenous

DRUG

Pemetrexed

intravenous

Sponsors & Collaborators

• Innovent Biologics (Suzhou) Co. Ltd.

  lead INDUSTRY

Principal Investigators

• Ba Yi · Tianjin Medical University Cancer Institute and Hospital

• Zhang Dahong · Zhejiang Provincial People's Hospital

• Guo Hongqian · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

• Fang Meiyu · Zhejiang Cancer Hospital

• Xie Yu · Hunan Cancer Hospital

• Liu Jisheng · First Affiliated Hospital of Soochow University

• Wang Ying · Zhejiang Provincial People's Hospital

• Wang Haiying · Shougang Hospital, Peking University

• Wang Mengzhao · Shougang Hospital, Peking University

• Lv Qiang · Jiangsu Provincial People's Hospital

• Li Xiangping · Nanfang Hospital, Southern Medical University

• Liu Guihong · The Affiliated Hospital of Xuzhou Medical University

• Mou Weiqi · Chongqing University Cancer Hospital

• Guo Wei · Peking Union Medical College

• Wang Wei · Hunan Cancer Hospital

• Xu Chongyuan · Nanfang Hospital, Southern Medical University

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

12 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-05-25

Primary Completion

2022-07-30

Completion

2022-07-30

Countries

• China

Study Locations